Bank of America Lowers Pfizer Price Target Amid COVID-19 Sales Decline

Pfizer Inc. (NYSE:PFE) faces a reassessment of its market position as Bank of America analyst Jason Gerberry has reduced the company’s price target from $28 to $27. This change, announced on December 16, 2023, comes in response to an anticipated decline in revenue from its COVID-19 franchise, which is now expected to erode more steeply than previously forecasted. Despite this reduction, Bank of America maintains a Neutral rating on the stock.

The adjustment in Pfizer’s financial outlook emphasizes a shift in focus towards the company’s strategy in the obesity market. Investors are particularly keen on the trial results related to Metsera, a recently acquired asset that aims to establish a foothold in the rapidly expanding weight-loss sector. As Pfizer navigates these challenges, the efficacy of Metsera could prove pivotal in enhancing its market appeal.

In another notable development, on December 17, 2023, Pfizer and its partner Astellas released positive topline results from the Phase 3 EV-304 trial, also known as KEYNOTE-B15. This study evaluated the combination treatment of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) for patients with muscle-invasive bladder cancer (MIBC). Results indicated a significant improvement in both event-free survival and overall survival when administered perioperatively, marking a potential advancement in treatment options for these patients.

The trial specifically targeted individuals eligible for cisplatin-based chemotherapy, which is currently the standard care for bladder cancer. The findings also met secondary endpoints, demonstrating a statistically significant improvement in the pathologic complete response rate compared to traditional neoadjuvant chemotherapy. This positions the PADCEV and Keytruda combination as a promising alternative treatment for MIBC, which affects approximately 30% of the over 614,000 bladder cancer diagnoses each year worldwide.

As Pfizer continues to adapt its strategies in light of these developments, the company’s ability to leverage its assets in both the COVID-19 and oncology domains will be closely monitored by investors and analysts alike. While the potential for growth remains, the market’s attention will likely remain on the outcomes of the Metsera trials and the impact of recent trial results on the company’s overall positioning in the biopharmaceutical sector.

Pfizer Inc. is involved in the discovery, development, manufacturing, marketing, and distribution of biopharmaceutical products globally. As the company navigates its future, comparisons with emerging AI stocks suggest that some investors may find more promising opportunities elsewhere. As the landscape evolves, stakeholders will need to assess where Pfizer fits within the broader market dynamics.